{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:06:08Z","timestamp":1774955168447,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"9634","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/s0140-6736(08)61075-2","type":"journal-article","created":{"date-parts":[[2008,7,19]],"date-time":"2008-07-19T04:37:18Z","timestamp":1216442238000},"page":"216-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1098,"title":["Long-term effects of A\u03b242 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial"],"prefix":"10.1016","volume":"372","author":[{"given":"Clive","family":"Holmes","sequence":"first","affiliation":[]},{"given":"Delphine","family":"Boche","sequence":"additional","affiliation":[]},{"given":"David","family":"Wilkinson","sequence":"additional","affiliation":[]},{"given":"Ghasem","family":"Yadegarfar","sequence":"additional","affiliation":[]},{"given":"Vivienne","family":"Hopkins","sequence":"additional","affiliation":[]},{"given":"Anthony","family":"Bayer","sequence":"additional","affiliation":[]},{"given":"Roy W","family":"Jones","sequence":"additional","affiliation":[]},{"given":"Roger","family":"Bullock","sequence":"additional","affiliation":[]},{"given":"Seth","family":"Love","sequence":"additional","affiliation":[]},{"given":"James W","family":"Neal","sequence":"additional","affiliation":[]},{"given":"Elina","family":"Zotova","sequence":"additional","affiliation":[]},{"given":"James AR","family":"Nicoll","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(08)61075-2_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/156720506775697098","article-title":"Has the amyloid cascade hypothesis for Alzheimer's disease been proved?","volume":"3","author":"Hardy","year":"2006","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/S0140-6736(08)61075-2_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/S0140-6736(08)61075-2_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","article-title":"Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD","volume":"64","author":"Bayer","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(08)61075-2_bib4","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(08)61075-2_bib5","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"key":"10.1016\/S0140-6736(08)61075-2_bib6","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/S0140-6736(08)61075-2_bib7","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","article-title":"Abeta species removal after abeta42 immunization","volume":"65","author":"Nicoll","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/S0140-6736(08)61075-2_bib8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archneur.64.4.583","article-title":"Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia","volume":"64","author":"Bombois","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/S0140-6736(08)61075-2_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(08)61075-2_bib10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","article-title":"Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease","volume":"38","author":"Hock","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/S0140-6736(08)61075-2_bib11","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.neuroscience.2006.10.020","article-title":"Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid","volume":"144","author":"Wilcock","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/S0140-6736(08)61075-2_bib12","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.1078259","article-title":"Cerebral hemorrhage after passive anti-Abeta immunotherapy","volume":"298","author":"Pfeifer","year":"2002","journal-title":"Science"},{"key":"10.1016\/S0140-6736(08)61075-2_bib13","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/S0140-6736(02)08695-6","article-title":"Predicting the failure of amyloid-beta vaccine","volume":"359","author":"Smith","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(08)61075-2_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1126\/science.301.5641.1847","article-title":"Good and bad amyloid antibodies","volume":"301","author":"Mattson","year":"2003","journal-title":"Science"},{"key":"10.1016\/S0140-6736(08)61075-2_bib15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(08)61075-2_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini mental state: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/S0140-6736(08)61075-2_bib17","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(08)61075-2_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1041610297004857","article-title":"Functional disability in Alzheimer's disease","volume":"9","author":"Gauthier","year":"1997","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/S0140-6736(08)61075-2_bib19","series-title":"The ICD-10 classification of mental and behavioural disorders","year":"1992"},{"issue":"4 suppl","key":"10.1016\/S0140-6736(08)61075-2_bib20","first-page":"S1","article-title":"Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease","volume":"18","author":"Anon","year":"1997","journal-title":"Neurobiol Aging"},{"key":"10.1016\/S0140-6736(08)61075-2_bib21","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ana.20592","article-title":"Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies","volume":"58","author":"Lee","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/S0140-6736(08)61075-2_bib22","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00005072-199904000-00008","article-title":"Alzheimer neuropathologic alterations in aged cognitively normal subjects","volume":"58","author":"Davis","year":"1999","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/S0140-6736(08)61075-2_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(00)03589-3","article-title":"Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(08)61075-2_bib24","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/brain\/awl178","article-title":"Two-year follow-up of amyloid deposition in patients with Alzheimer's disease","volume":"129","author":"Engler","year":"2006","journal-title":"Brain"},{"key":"10.1016\/S0140-6736(08)61075-2_bib25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/85525","article-title":"Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy","volume":"7","author":"Bacskai","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/S0140-6736(08)61075-2_bib26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1742-2094-1-24","article-title":"Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage","volume":"1","author":"Wilcock","year":"2004","journal-title":"J Neuroinflammation"},{"key":"10.1016\/S0140-6736(08)61075-2_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/416535a","article-title":"Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo","volume":"416","author":"Walsh","year":"2002","journal-title":"Nature"},{"key":"10.1016\/S0140-6736(08)61075-2_bib28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature04533","article-title":"A specific amyloid-beta protein assembly in the brain impairs memory","volume":"440","author":"Lesne","year":"2006","journal-title":"Nature"},{"key":"10.1016\/S0140-6736(08)61075-2_bib29","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.2353\/ajpath.2006.060269","article-title":"Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis","volume":"169","author":"Patton","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/S0140-6736(08)61075-2_bib30","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nri1843","article-title":"Immunology and immunotherapy of Alzheimer's disease","volume":"6","author":"Weiner","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/S0140-6736(08)61075-2_bib31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI200318104","article-title":"Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease","volume":"112","author":"Monsonego","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/S0140-6736(08)61075-2_bib32","doi-asserted-by":"crossref","unstructured":"Pride MW, Black RS, Hagen M, et al. Evaluation of potential immunologic mechanisms in the pathogenesis of treatment-induced meningoencephalitis in Alzheimer's disease patients treated with AN1792 (QS-21). International Conference on Alzheimer's Disease and Related Disorders; Philadelphia, PA, USA; July 17\u201322, 2004. P4-348.","DOI":"10.1016\/S0197-4580(04)81906-7"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673608610752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673608610752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T23:55:46Z","timestamp":1758844546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673608610752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":32,"journal-issue":{"issue":"9634","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0140673608610752"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(08)61075-2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1120452.576650","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1120452.14741239","asserted-by":"object"}]},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effects of A\u03b242 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(08)61075-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(08)61047-8","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}